Zeneca ZD6169 and its analogs from a novel series of anilide tertiary carbinols: in vitro KATP channel opening activity in bladder detrusor.
The potassium (K+) channel opening activity of Zeneca ZD6169 and one of its pyridylsulfonyl analogs from the anilide tertiary carbinol series was ascertained. Their mechanoinhibitory effects on the myogenic activity of the guinea pig bladder detrusor muscle were measured in a set of functional assays. Elevating the K+ concentration in the tissue bath from 15 to 80 mmol/l increased the IC50 value of ZD6169 from 1.61 +/- 0.22 223 +/- 37 mumol/l. This result suggests that ZD6169 may act as a K+ channel opener. Similar to the prototypic ATP-sensitive K+ (KATP) channel opener cromakalim, the K+ channel openers from the anilide tertiary carbinol series displayed stereoselective mechanoinhibitory activity only in the test protocol in which the detrusor was stimulated with 15 mmol/l KCl. Being the active enantiomer, ZD6169 has an activity more than 30-fold higher than the less active enantiomer. ZD6169 at 10 mumol/l hyperpolarized the guinea pig detrusor membrane potential by 6.1 +/- 1.2 mV and increased the whole cell KATP current in isolated guinea pig smooth muscle cells by 34.9 +/- 7.9 pA. This is comparable to the increase of 26.8 +/- 5.0 pA obtained with 10 mumol/l of lemakalim, the active enantiomer of cromakalim. The K+ channel opening activity of ZD6169 and the pyridylsulfonyl analog was competitively antagonized by the KATP channel blocker glibenclamide in the guinea pig detrusor with a pA2 value of 7.2. This activity, however, was unaffected by blockers of small and large conductance Ca-dependent K+ channels, such as apamin and charybdotoxin, respectively. The present study showed that Zeneca ZD6169 and its analog from the anilide tertiary carbinol series are K+ channel openers that activate KATP channels in vitro to relax bladder detrusors.
Li
J H
JH
Department of Pharmacology, Zeneca Inc., Wilmington, Del 19897, USA.
Yasay
G D
GD
Zografos
P
P
Kau
S T
ST
Ohnmacht
C J
CJ
Russell
K
K
Empfield
J R
JR
Brown
F J
FJ
Trainor
D A
DA
Bonev
A D
AD
D000255:Adenosine Triphosphate / Q000502:physiology; D000577:Amides / Q000737:chemistry / Q000494:pharmacology*; D000818:Animals; D001577:Benzophenones / Q000737:chemistry / Q000494:pharmacology*; D002478:Cells, Cultured; D046508:Culture Techniques; D004594:Electrophysiology; D006168:Guinea Pigs; D008297:Male; D008564:Membrane Potentials / Q000187:drug effects; D000432:Methanol / Q000737:chemistry; D009130:Muscle, Smooth / Q000187:drug effects*; D011188:Potassium / Q000378:metabolism; D026902:Potassium Channel Blockers; D015221:Potassium Channels / Q000145:classification / Q000187:drug effects*; D001743:Urinary Bladder / Q000187:drug effects* / Q000502:physiology
D000577:Amides; D001577:Benzophenones; D026902:Potassium Channel Blockers; D015221:Potassium Channels; C095007:Zeneca ZD 6169; D000255:Adenosine Triphosphate; D011188:Potassium; D000432:Methanol